AstraZeneca bets on next-generation cancer therapy with $2 billion Fusion deal
Reuters
Published Mar 19, 2024 07:10
Updated Mar 19, 2024 14:41
By Yadarisa Shabong and Manas Mishra
(Reuters) -AstraZeneca said on Tuesday it will buy Canadian drug developer Fusion Pharmaceuticals Inc for $2 billion in cash as the Anglo-Swedish drugmaker bets on next-generation cancer treatments.
The deal gives AstraZeneca (NASDAQ:AZN) a foothold in the radiopharmaceutical drugs market, which has seen increasing investor interest since 2021 when data from Novartis (LON:0QLR)' treatment showed that the drug extended survival for prostate cancer patients.
The Novartis drug was approved in 2022 and the space has seen a flurry of deals since then, including Eli Lilly (NYSE:LLY)'s $1.4 billion acquisition of Point Biopharma and Bristol Myers Squibb's $4.1 billion deal for RayzeBio last year.
AstraZeneca will pay $21 per Fusion share, a premium of more than 97% to the U.S.-listed company's closing price on Monday. Fusion's shares doubled to $21.46 in US premarket trading.
Fusion is developing "next-generation" radioconjugates, which deliver a radioactive isotope directly to cancer cells through precise targeting using molecules.
Fusion's most advanced therapy is called FPI-2265, which is currently in a mid-stage trial to treat patients with metastatic castration-resistant prostate cancer.
"Between 30 and 50% of patients with cancer today receive radiotherapy at some point during treatment, and the acquisition of Fusion furthers our ambition to transform this aspect of care with next-generation radioconjugates," said Susan Galbraith, executive vice president, Oncology R&D at AstraZeneca.
Older radiotherapy and chemotherapy have been the mainstays of cancer treatment for decades.
AstraZeneca has been working on other approaches to develop more targeted cancer treatments, including antibody-drug conjugates and RCs.
"The deal has solid strategic logic, potentially allowing Astra to combine its existing antibody portfolio with radioconjugate payloads," J.P.Morgan wrote in a note.
AstraZeneca will also pay a non-transferable contingent value right of $3 per share, taking the combined transaction value to about $2.4 billion.
AstraZeneca's oncology sales were $17.15 billion in 2023, making up more than a third of its total revenue.
Get The App
The Fusion deal follows a string of others in the past few months, including its $1.05 billion purchase of Amolyt Pharma last week. In late 2023, AstraZeneca signed deals in several spaces including oncology, vaccine and anti-obesity - through a licensing deal.
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.